Downstream Processing: A Primer - NIBRT's Ian Nelligan on what to expect when starting a downstream process. - BioPharm International

ADVERTISEMENT

Downstream Processing: A Primer
NIBRT's Ian Nelligan on what to expect when starting a downstream process.

BioPharm International
Volume 25, Issue 10, pp. 68-69

BEST PRACTICES

BioPharm: Can you offer any best practices for embarking on a downstream manufacturing process overall?

Nelligan: Be open to change. The industry today is like the computer industry of the 1970s—we have seen a boom in technology that is not slowing down. Our knowledge about how to best complete bioprocessing steps increases day to day, and that knowledge is constantly being transferred into operations. Every day, we see new equipment arrive, better equipment, cheaper equipment—there are all sorts of innovations happening.

In the industry today, there is a huge worldwide demand for therapeutic protein drugs that is showing double digit growth. A lot of money is being invested in the industry in new products and processes, and at the same time, there is a drive to reduce cost, to improve productivity, and to become more efficient. We have passed the stage where, perhaps five or six years ago, it was important to make drugs at any price because they were so important. Now the goal is to make them as inexpensively and efficiently as possible.

The cost of goods is becoming more and more important, especially when trying to break into new markets. Customers are demanding that the price of biopharmaceutical products is reduced and better technology and more automated processes are developed to enable this. These are the pressures we face in the biopharmaceutical industry. The objective is to make more powerful, more affordable drug products going forward.

REFERENCE

1. "Upstream Processing: A Primer," BioPharm Intl. 25 (9) 62–64 (2012).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here